

S 366

FLAT Prices Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 6, 2019

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S921-9)

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S921-922) (Feb 6, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/366>

Sponsor

Name: Sen. Durbin, Richard J. [D-IL]

Party: Democratic • **State:** IL • **Chamber:** Senate

Cosponsors (6 total)

| Cosponsor | Party / State | Role | Date Joined |
|---------------------------------|---------------|------|--------------|
| Sen. Blumenthal, Richard [D-CT] | D · CT | | Feb 6, 2019 |
| Sen. Harris, Kamala D. [D-CA] | D · CA | | Feb 6, 2019 |
| Sen. Klobuchar, Amy [D-MN] | D · MN | | Feb 6, 2019 |
| Sen. Smith, Tina [D-MN] | D · MN | | Feb 6, 2019 |
| Sen. Brown, Sherrod [D-OH] | D · OH | | Feb 7, 2019 |
| Sen. Peters, Gary C. [D-MI] | D · MI | | Sep 25, 2019 |

Committee Activity

| Committee | Chamber | Activity | Date |
|--|---------|-------------|-------------|
| Health, Education, Labor, and Pensions Committee | Senate | Referred To | Feb 6, 2019 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|-------------|----------------|--|
| 116 HR 1188 | Identical bill | Feb 14, 2019: Referred to the Subcommittee on Health. |

Forcing Limits on Abusive and Tumultuous Prices or the FLAT Prices Act

This bill directs the Food and Drug Administration to reduce the market exclusivity of an approved prescription drug if the drug manufacturer increases the drug's price by more than a specified percentage. This reduction may be waived under specified circumstances.

Actions Timeline

- **Feb 6, 2019:** Introduced in Senate
- **Feb 6, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S921-922)